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Abstract
The Herpes Simplex Virus 1 (HSV-1)-encoded ICP22 protein plays an important role in viral infection and affects expression
of host cell genes. ICP22 is known to reduce the global level of serine (Ser)2 phosphorylation of the Tyr1Ser2Pro3Thr4-
Ser5Pro6Ser7 heptapeptide repeats comprising the carboxy-terminal domain (CTD) of the large subunit of RNA polymerase
(pol) II. Accordingly, ICP22 is thought to associate with and inhibit the activity of the positive-transcription elongation factor
b (P-TEFb) pol II CTD Ser2 kinase. We show here that ICP22 causes loss of CTD Ser2 phosphorylation from pol II engaged in
transcription of protein-coding genes following ectopic expression in HeLa cells and that recombinant ICP22 interacts with
the CDK9 subunit of recombinant P-TEFb. ICP22 also interacts with pol II in vitro. Residues 193 to 256 of ICP22 are sufficient
for interaction with CDK9 and inhibition of pol II CTD Ser2 phosphorylation but do not interact with pol II. These results
indicate that discrete regions of ICP22 interact with either CDK9 or pol II and that ICP22 interacts directly with CDK9 to
inhibit expression of host cell genes.
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Introduction
Herpesviruses are significant human pathogens associated with
a range of mild to severe diseases. Although Herpes Simplex Virus
(HSV) infections are generally self-limiting in healthy individuals,
they can cause inflammation of the brain and eye and pose a
significant mortality risk to infants and immuno-compromised
adults [1–5].
The HSV ICP22 protein (encoded by the US1 gene) is required
for efficient viral replication, infection and latency in cell and
animal models and regulates expression of some viral late genes
[6–9]. ICP22 also counteracts the effect of IFN-b and has been
implicated in the down-regulation of cellular genes [9–12].
Homologues of ICP22 are encoded by all alphaherpesviruses.
An N-terminal-truncated protein called US1.5 is also expressed
from the US1 gene [12]. Translation of US1.5 has been variously
reported to initiate at an ATG within residues 90–92, 171–173 or
147–149 [13–15] and functional differences between ICP22 and
US1.5 have not yet been completely characterized. However,
US1.5 is dispensable for both efficient acute virus replication and
virus-induced chaperone-enriched (VICE) domain formation [9].
Recently, Kolb and colleagues identified a conserved region
from residues 193 to 256 encompassing motifs predicted to be
cyclin binding sites [2].
The carboxyl-terminal domain (CTD) of the large subunit of
RNA polymerase II (pol II) comprises multiple repeats of the
consensus sequence Tyr1Ser2Pro3Thr4Ser5Pro6Ser7 and all
three serines (Ser) undergo dynamic phosphorylation and dephos-
phorylation during transcription [16–24]. Ectopic expression of
ICP22 causes the loss of phosphorylation of Ser2 [25], a mark
associated with productive elongation [19,23]. Positive transcrip-
tion elongation factor b (P-TEFb), which comprises the CDK9
kinase and a Cyclin T subunit, is thought to be a major CTD Ser2
kinase. There is evidence that ICP22 physically interacts with P-
TEFb [26,27] and it has been suggested that ICP22 inhibits
CDK9 kinase activity [28]. However, it has not yet been
definitively demonstrated whether ICP22 interacts with P-TEFb
directly. In addition, the effect of ICP22 on expression of host cell
genes has not been fully characterized.
Here we show that ICP22 expression causes loss of phosphor-
ylation of Ser2 and Tyr1 of the pol II CTD heptapeptide repeat
without markedly affecting phosphorylation of Ser5 and Ser7.
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These results are in line with the effect of ICP22 expression in other
systems. Chromatin immunoprecipitation (ChIP) analysis indicates
that pol II association with host cell genes and CTD Ser2
phosphorylation on transcriptionally-engaged pol II are drastically
affected by ectopic expression of either full-length ICP22 or a
truncated version comprising the conserved domain from amino
acids 193 to 256. GST-mediated pull-down assays using recombi-
nant ICP22 and recombinant P-TEFb indicate that these two
proteins interact directly and that residues 193 to 256 of ICP22 are
sufficient for this interaction. Moreover, a distinct region of ICP22 is
required for interaction with pol II in HeLa nuclear extracts. On the
basis of these results, we propose that ICP22 interacts with P-TEFb
directly and with pol II, either directly or indirectly, to downregulate
expression of host cell genes and facilitate the viral life cycle.
Results
Transient ectopic expression of ICP22 causes specific loss
of pol II CTD Ser2 and Tyr1 phosphorylation
Full length ICP22 and the shorter form, Us1.5 are efficiently
expressed from an expression vector containing the ICP22 open
reading frame followed by three tandem Myc epitope tags after
transient transfection into HeLa cells (Figure 1A). An N-terminal-
truncated protein comprising residues 171 to 420 migrates the
same as Us1.5, (Figure 1B) supporting the notion that translation
of Us1.5 initiates at the AUG at residues 171-173 in HeLa cells, as
noted in other cases [14]. In line with previous studies [25], ICP22
(and/or Us1.5) expression causes loss of phosphorylation of Ser2 of
the pol II CTD, whereas phosphorylation of Ser5 is unaffected
(Figure 1C). In addition, phosphorylation of the other serine in the
CTD heptapeptide, Ser7, which also occurs during transcription
[19,29–31], is not affected (Figure 1C). However, phosphorylation
of Tyr1 is reduced (Figure 1C).
These results indicate that ICP22 specifically affects the global
levels of phosphorylation of the serine at position 2 and the
tyrosine at position 1 of the pol II CTD heptapeptide in HeLa
cells.
Amino acids 193 to 256 of ICP22 delimit a region conserved in
the alpha-herpesviruses (Figure 2A), which contains predicted
cyclin-binding domains [2]. Expression of this subdomain of
ICP22 region causes loss of Ser2 phosphorylation of the pol II
CTD as effectively as the full-length ICP22 (Figure 2B and 2C).
Ectopic expression of ICP22 or the 193–256 subdomain
causes loss of Ser2 phosphorylation from pol II
transcribing host cell protein-coding genes
ICP22 expression is associated with a decrease in the steady-
state level of RNA from a number of host cell genes [32].
However, the effect of ICP22 expression on CTD phosphorylation
of transcriptionally-engaged pol II has not yet been determined.
We carried out chromatin immunoprecipitation (ChIP) analyses of
pol II and pol II CTD Ser2 and Ser5 phosphorylation on two
candidate genes, PLK2 and EIF2S3 (Figure 3A) after transfection
of vector (pcDNA3), the whole ICP22 coding region or the 193–
256 subdomain (Figure 3B–F). In untransfected cells and cells
transfected with pcDNA3, pol II levels are high near the promoter
(primer 2) and considerably lower further into the gene (primer 3)
Figure 1. Transient ectopic expression of ICP22 causes specific
loss of pol II CTD Ser2 and Tyr1 phosphorylation. (A) Myc
epitope-tagged ICP22 and US1.5 were ectopically expressed in HeLa
cells from a transfected expression vector containing the ICP22 open-
reading frame followed by three Myc epitope tags. pcDNA3 was used as
the control in this and all subsequent transfections. An anti-Myc tag
antibody was used for the western blot analysis and the positions of
full-length ICP22 and US1.5 are noted. a-tubulin was used as a loading
control (B) Western blot analysis was performed as described in (A). The
antibody used is indicated on the right. (C) Western blot analysis was
carried out using antibodies to the CTD phosphorylation marks
indicated on the right. CTCF was used as a loading control.
doi:10.1371/journal.pone.0107654.g001
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(Figure 3A and Figure S1 in File S1), which is the typical pattern
of pol II association with human protein-coding genes [20,33]. Pol
II levels associated with the gene body are severely reduced on
both genes following expression of either full-length Myc-ICP22 or
Myc-193-256 (Figure 3B), suggesting that these proteins inhibit
pol II-dependent transcription. As pol II levels close to the
transcription start site are not adversely affected, transcription
elongation rather than initiation of transcription appears to be
affected. Ser2 phosphorylation of the CTD of transcriptionally-
engaged pol II is also drastically reduced following expression of
full-length Myc-ICP22 and Myc-193-256 (Figure 3C, D). In
contrast, pol II CTD Ser5 phosphorylation is not adversely
affected (Figure 3E, F).
The drastic loss of Ser2 phosphorylation from the CTD of pol II
associated with the PLK2 gene suggests that the level of transfection
of ICP22 is high and that Myc-ICP22 and Myc-193-256 are
expressed in most cells. ICP22 is reported to localize in the nucleus
in transfected and infected cells [34–36]. We have therefore
analysed HeLa cells transfected with empty pcDNA3 and Myc-
ICP22 by immunofluorescence (IF) using an antibody to an N-
terminal region of ICP22 to investigate both the level of transfection
and the nuclear localization of ICP22 (Figure S2 in File S1). The
level of transfection withMyc-ICP22 is very high (greater than 90%)
and ICP22 appears to be localized predominantly in the nucleus,
consistent with previous findings [34–36] and as expected for a
protein associated with the transcription apparatus.
The level of Ser2 phosphorylation of the pol II CTD associated
with primer pair 2 of the EIF2S3 gene is less affected than the
same region of the PLK2 gene (Figure 3C), suggesting some gene-
specific variability in the ability of ICP22 to inhibit CTD Ser2
phosphorylation.
The effects on pol II and pol II CTD Ser2 phosphorylation are
similar to those caused by small molecule inhibitors of CDK9, like
DRB [20]. In support of this notion, ectopic expression of ICP22
inhibits pol II association with the b-actin gene beyond +1000 bp
and pol II CTD Ser2 phosphorylation (Figure S3 in File S1), as we
have previously shown for DRB using the same cells [20]. These
results indicate that both full-length ICP22 and the shorter form
comprising amino acids 193–256 effectively inhibit CTD phos-
phorylation of pol II transcribing host cell genes and effectively
reduce the level of pol II associated with the body of the PLK2,
EIF2S3 and b-actin genes. The drop in pol II ChIP levels
downstream of the promoter is consistent with inhibition of
transcription elongation. The inhibition of pol II CTD Ser2
phosphorylation suggests that the effect on pol II levels could be
due to inhibition of the CDK9 kinase activity of P-TEFb causing a
defect in transcription elongation.
ICP22 and 193–256 also cause a drop in the level of intronic
RNA from the EIF2S3 gene, as measured by quantitative reverse
transcription (qRT)PCR with primers specific for intron 2 (Figure
S4 in File S1). This is likely to reflect the loss of nascent transcripts,
consistent with an effect on transcription elongation.
Figure 2. Ectopic expression of ICP22 or the 193–256
subdomain causes loss of pol II CTD Ser2 phosphorylation.
Alignment of the conserved core motif within ICP22 of the
alphaherpesviruses showing the degree of conservation according to
the scheme above. Alignments were generated using PRALINE (http://
www.ibi.vu.nl/programs/pralinewww/). Asterisks indicate identical res-
idues. Accession Nos. AEDO2597, AEV91400, AAA46092, CAA54262,
AEL30878 (B) Top, diagram of full-length ICP22 and 193–256 showing
the position of the alphaherpesvirus conserved core motif and the
epiptope tags (Myc). Bottom, the results of western blot analysis of
extracts from HeLa cells transfected with the constructs indicated using
antibodies to the Myc tag. a-tubulin was used as a loading control. (C)
Western blot analysis of whole-cell extract from HeLa cells transfected
with the constructs indicated using antibodies to the Ser2P CTD
phosphorylation mark. RPAP2 was used as a loading control.
doi:10.1371/journal.pone.0107654.g002
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ICP22 is associated with cellular genes but does not
affect recruitment of CDK9
Several different mechanisms could account for the effect of
ICP22 on the level of pol II. For example, ICP22 could affect the
recruitment of CDK9 to cellular genes. Alternatively, ICP22 could
be recruited to genes to inhibit CDK9 activity at the site of
transcription. To investigate these two possibilities, we carried out
ChIP analysis on the PLK2 gene with an antibody to the Myc
Figure 3. Ectopic expression of ICP22 or the 193–256 subdomain causes loss of Ser2 phosphorylation from pol II transcribing host
cell protein-coding genes. (A) Diagrams of the PLK2 and EIF2S3 genes, with the position of chromatin immunoprecipitation (ChIP) primer pairs
indicated. (B), (C), (E) The results of ChIP analysis using the antibodies indicated on the left after transfection of vectors expressing the Myc-tagged
proteins indicated. (D), (F) The ratio of the CTD modification to pol II as indicated at the left.
doi:10.1371/journal.pone.0107654.g003
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epitope-tag following expression of Myc-ICP22 (Figure 4). ICP22
is found associated with the PLK2 gene, close to the start site of
transcription (Figure 4) in a region where pol II levels remain high
after expression of ICP22 (Figure 3B and Figure S3B in File S1).
ChIP analysis of CDK9 on the PLK2 gene following transient
transfection of Myc-ICP22 indicates that ICP22 does not
significantly alter the pattern of association of CDK9 (Figure 4C).
The loss of pol II from the primer 3 region of the PLK2 gene
caused by ICP22 (Figure 3A) does not cause a loss of CDK9,
suggesting that CDK9 can be recruited to this gene independently
of pol II. These results indicate that ICP22 is recruited to cellular
genes and inhibits CDK9 at the site of transcription rather than
blocking CDK9 recruitment.
ICP22 interacts with pol II and CDK9
To further understand the molecular mechanism by which
ICP22 affects pol II CTD Ser2 phosphorylation, we performed
GST-ICP22- and GST-193-256-mediated pull-down, using either
cell extract (Figure 5A) or recombinant P-TEFb (Figure 5B).
GST-ICP22 interacts with both CDK9 and pol II in cell extract
whereas GST-193-256 interacts only with CDK9 (Figure 5A).
Both recombinant full-length ICP22 and recombinant residues
193–256 interact with recombinant CDK9 (Figure 5B), indicating
that the interaction between ICP22 and CDK9 is direct and that
residues 193 to 256 are sufficient.
Discussion
ICP22 is a multifunctional protein that plays important roles
during HSV-1 infection [7,8,10] and homologues are likely to be
important during the infection cycle of all alphaherpesviruses.
Insights into the molecular mechanism of ICP22 function are
critical for a full understanding of the role this protein plays in viral
infection and the development of new anti-Herpes strategies that
target ICP22. In addition, dissecting the interplay between ICP22
and the host transcriptional apparatus could shed light on key
regulatory steps during transcription.
Figure 4. ICP22 is associated with cellular genes but does not
affect recruitment of CDK9. (A) Diagram of the PLK2 gene, with the
position of chromatin immunoprecipitation (ChIP) primer pairs indicat-
ed. (B), (C) ChIP analysis using the antibodies indicated on the left after
transfection of vectors expressing the Myc-tagged ICP22 or pcDNA3
(control) as indicated.
doi:10.1371/journal.pone.0107654.g004
Figure 5. ICP22 interacts with pol II and CDK9. (A) GST-mediated pull-down from HeLa nuclear extract with the recombinant proteins indicated
at the top, followed by western blot analysis using anti-pol II and anti-CDK9 antibodies. On the right, a diagram of full-length ICP22 and 193–256
shows the position of the alphaherpesvirus conserved core motif and the GST tags. (B) GST-mediated pull-down of recombinant P-TEFb by the
recombinant proteins indicated at the top followed by western blot analysis using an anti-CDK9 antibody.
doi:10.1371/journal.pone.0107654.g005
HSV-1 ICP22 Inhibition of Transcription Elongation
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ICP22 was shown to cause loss of phosphorylation of Ser2 of the
pol II CTD [37], a mark associated with productive transcription
elongation [19]. P-TEFb is thought to be a major CTD Ser2
kinase [19] and it has been suggested that ICP22 interacts directly
with P-TEFb to inhibit the activity of its CDK9 kinase [28]. We
have confirmed that ICP22 causes specific loss of phosphorylation
of Ser2 of the CTD without markedly affecting phosphorylation of
Ser5 or Ser7 in HeLa cells. The specific loss of Ser2 phosphor-
ylation therefore recapitulates the effect of ICP22 expression in
other systems [25,37]. These results also strengthen the conclusion
that ICP22 does not affect the kinase activity of CDK7, which
phosphorylates both Ser5 and Ser7 soon after initiation
[23,38,39]. However, CTD Tyr1 phosphorylation is affected by
ICP22. Tyr1 phosphorylation is thought to be carried out by c-Abl
[30,31] and the highest levels of Tyr1 phosphorylation are
associated with promoters and enhancers [40], suggesting a role
at an early stage of the transcription cycle. Inhibition of Tyr1
phosphorylation may play an important role in ICP22-mediated
regulation of transcription of host and viral genes.
We show that the interaction between ICP22 and CDK9 is
direct, suggesting a direct interaction with P-TEFb. Furthermore,
our results indicate that the region of ICP22 conserved in
Figure 6. Model for the role of ICP22 in inhibition of pol II CTD Ser2 phosphorylation. In uninfected cells (top panel), the negative
elongation factor (NELF) and the DRB-sensitivity-inducing factor (DSIF) enhance pol II stalling. Subsequent recruitment of P-TEFb allows
phosphorylation of DSIF, NELF and Ser2 of the pol II CTD, which leads to productive elongation. In the context of HSV-1-infected cells (bottom panel),
ICP22 associates with P-TEFb and inhibits the kinase activity of CDK9 at the site of transcription, as indicated by the loss of phosphorylation of Ser2 of
the pol II CTD, NELF and DSIF. As a consequence, the transition to productive elongation is inhibited. Interaction between ICP22 and pol II is not
necessary to recruit ICP22 to genes or inhibit CDK9 when ICP22 is ectopically expressed in cells on its own. However, the interaction between pol II
and ICP22 may be necessary to recruit ICP22 to host cell genes in HSV1-infected cells. Alternatively, interaction between ICP22 and pol II may play a
role in regulation of viral gene expression by ICP22.
doi:10.1371/journal.pone.0107654.g006
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alphaherpesviruses, residues 193–256, is sufficient for this inter-
action, suggesting that ICP22 from other alphaherpesviruses is also
likely to interact with and inhibit P-TEFb. As the GST-ICP22
proteins we have used were purified from bacteria, they are
unlikely to be post-translationally modified by, for example,
phosphorylation, methylation, ubiquitylation in the same way as
they would be when expressed in mammalian cells. Thus, no
modification of ICP22 that would be added only during expression
in mammalian cells is necessary for the interaction between ICP22
and CDK9. As the Cyclin T1 in the recombinant P-TEFb is
truncated, our results further indicate that residues 1–266 of
CyclinT1 are sufficient for any interaction with the P-TEFb
complex. However, additional studies will be required to fully map
region(s) of CDK9/Cyclin T1 involved in the interaction.
Our ChIP studies of the PLK2, EIF2S3 and b-actin genes
indicate that CTD Ser2 phosphorylation on transcribing pol II is
drastically affected by expression of either full-length ICP22 or the
truncated form comprising residues 193–256. Our data suggest
that transcription elongation rather than initiation of transcription
is affected, consistent with the role of P-TEFb in overcoming an
early-elongation checkpoint by phosphorylating the pol II CTD,
NELF and DSIF [41]. Although the loss of pol II CTD Ser2
phosphorylation suggests that phosphorylation of NELF and DSIF
is likely also to be inhibited, this remains to be determined.
Our finding that ICP22 inhibits CTD phosphorylation at the
site of transcription without affecting CDK9 recruitment contrasts
with the finding that ICP22 reduces Cyclin T1 association with the
HSV-1 a, b and c promoters in HSV-1 infected cells [27]. This
may reflect differences in ICP22 action when it is ectopically
expressed in cells on its own in our experiments and ICP22 action
in the context of infection, differences in the effect on host cell and
viral genes or that ICP22 has different effects on CDK9 and
Cyclin T1 association.
Finally, our pull-down studies have also revealed a hitherto-
unsuspected interaction between ICP22 and pol II that is likely to
be important for the in vivo function of ICP22. As residues 193–
256 do not interact with pol II, but inhibit pol II CTD Ser2
phosphorylation and pol II levels, the interaction between ICP22
and pol II does not appear to be required for CDK9 inhibition.
On the basis of the data presented here, our current working
model is that ICP22 is recruited to host cell genes where it directly
associates with P-TEFb to inhibit the CDK9 kinase activity, which
results in downregulation of expression of host cell genes at the
level of transcription elongation (Figure 6). The level of pol II at
the beginning of the PLK2 and EIF2S3 genes remains high after
ICP22 expression, suggesting that pol II is poised here after CDK9
inhibition rather than released. Interaction between pol II and
ICP22 could help recruitment of the full-length ICP22 to host cell
genes when ICP22 levels are low, for example at the early stages of
infection, or in the context of viral infection. Alternatively, the
interaction between pol II and ICP22 may play a role in regulation
of expression of viral genes. ICP22 has been shown to repress
activation of reporter gene transcription by the HSV-1 ICP0
protein, to repress transcription from the HSV-1a, b and c
promoters and to upregulate expression of some HSV-1 late genes
[9,27,42]. VP16 can overcome ICP22-mediated repression of the
HSV-1 a promoter [27], emphasizing that ICP22 function can be
modulated by the activity of other viral proteins. The interaction
between ICP22 and pol II could therefore be important for either
repression or activation of viral genes at specific stages of the viral
life cycle.
Materials and Methods
Cell lines
HeLa cells were grown in DMEM medium supplemented with
10% fetal calf serum, 100 U/mL penicillin, and 2 mM L-
glutamine at 37uC and 5% CO2.
Expression Constructs
To generate Myc-ICP22 and Myc-193-256, three tandem Myc
epitopes were cloned at the C terminus of the ICP22 coding region
and residues 193–256 of ICP22 in pcDNA3. To make GST-
ICP22 and GST-193-256, the coding regions were cloned into
pGEX-6P-1. The identity of all plasmid constructs was verified by
sequence analysis.
RNA preparation
RNA was extracted from 66106 cells transfected with pcDNA3,
Myc-ICP22 or Myc-193-256 HeLa cells using TRIzol (Invitrogen)
according to the manufacturer’s instructions. Reverse-transcrip-
tion (RT) was performed with 1 mg of RNA using random
hexamers with the SuperScriptIII kit (Invitrogen) according to the
manufacturer’s instructions. cDNA was amplified by qRT-PCR
using QuantiTect SYBR Green PCR (Qiagen) using a Rotor-
Gene RG-3000 (Corbett Research). The sequences of primers are
given in Table 1.
Table 1. Sequence of primer sets used for qRT-PCR analysis.
Name Sequence of forward primer Sequence of reverse primer
PLK2 1 AAGTGTCTCCTCTGTACCAGGA GGAATCATGACCAGGAAATGTACGG
PLK2 2 ACCGGGGTGTTGGGTGCTAGT ATAGTCCGCAAAAGCTCCATG
EIF2S3 1 AACCAGCGAACTTCAGACGCT GTCCCCAGCTTGTTCCCAGAGA
EIF2S3 2 GAGAAGCTGGAGTGACTCTAGG CACTGACTAGTCCCAATACC
EIF2S3 3 GATGGTGGCAAGATGTAGATAGCA CGTCAACTTGGTAACATCCTGCAATG
EIF2S3 4 TACAGGCCTTGAACTACTGC CTTAGCATAGGTTGTTCGGAGG
5.8S CAAGCGACGCTCAGACAGG GTGGATCACTCGGCTCGTGC
b-actin 1 GCTGCGGCTGGGTAGGTTTG CACTTAGAAGTCGCAGGACC
b-actin 2 GGGCAACCGGCGGGGTCTTT ACGCAGTTAGCGCCCAAAGG
b-actin 3 CCCCATCGAGCACGGCATCGTC CACCTGGGTCATCTTCTCGCGGT
doi:10.1371/journal.pone.0107654.t001
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Chromatin Immunoprecipitation
HeLa cells were transfected with pcDNA3, Myc-ICP22 and
Myc-193-256 vectors using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions before being subject-
ed to ChIP analysis as detailed [43]. ChIP samples were analyzed
by qRT-PCR using QuantiTect SYBR Green PCR (Qiagen) and
Rotor-Gene RG-3000 (Corbett Research). Error bars indicate the
standard deviation from at least three independent experiments.
Final ChIP values are expressed as a percentage of the total DNA
input after deduction of the signal obtained using rabbit IgG as a
negative control. Antibodies against pol II (sc-899) and CDK9 (sc-
484) were obtained from Santa Cruz Biotechnology. Antibodies
against Ser2P (ab5095), Ser5P (ab5131) and the Myc-tag (ab9132)
were obtained from Abcam. The sequences of primers are given in
Table 1.
Western Blot Analysis
Western blotting was carried out as described previously [16]
using proteins harvested from cells boiled in Laemmli buffer
(50 mM Tris (pH6.8), 2% sodium dodecyl sulphate, 5% b-
mercaptoethanol, 10% glycerol, 0.1% bromophenol blue) and
antibodies against pol II diluted 1:200 (sc-899, Santa Cruz), pol II
CTD Ser2P diluted 1:1000 (ab5095, Abcam), Ser5P diluted
1:1000 (ab5131, Abcam), Ser7P diluted 1:200 [29], Tyr1P diluted
1:200 (61383, Active motif), RPAP2 diluted 1:1000 (17401-1-AP,
Proteintech), CTCF diluted 1:1000 (07–729, Millipore), Myc-tag
diluted 1:1000 (ab9132, Abcam), CDK9 diluted 1:500 (sc-484,
Santa Cruz) and a-tubulin diluted 1:1000 (200-301-880, Tebu-
bio).
Immunofluorescence
Cells for immunofluorescence were plated into 6-well trays
containing one coverslip per well and transfected with pcDNA3 or
Myc-ICP22 plasmid DNA using Lipofectamine 2000 according to
the manufacture’s instructions. Cells were washed with PBS and
fixed for 15 min at room temperature with 4% PFA/2% sucrose
in 1xPBS. The samples were then blocked and incubated for 1 h
with the primary antibody diluted 1:100 (Hhv11 ICP22 antibody,
orb159247). Following 36 washes with PBS +0,1% Triton, the
secondary antibody (Alexa Fluor 488 anti-rabbit, A21206) was
added to the blocking solution and incubated for 30 minutes.
Three additional washes were carried out before the coverslips
were mounted (EverBrite Mounting with DAPI, Biotium 23002).
Samples were then examined with a Zeiss AxioObserver Z1 206
and images processed using Fiji Image J [44] and images processed
using Adobe Photoshop software. Dapi was detected with Zeiss
Filter set 02 and Alexa Fluor 488 with Zeiss Filter set 38.
Protein Purification and GST Pull-down Assays
GST-ICP22, GST-193-256 and GST were purified from
Escherichia coli (Rosetta cells) and immobilized on Sepharose
4B-gluthatione beads (GE Healthcare). Hela nuclear extract (NE)
was produced as described [45]. 400 ml of HeLa NE was
incubated at 4uC for 2 h with immobilized GST-tagged protein
or GST. The beads were washed with 160.15 M HEGN,
460.3 M HEGN, 160.15 M HEGN (HEGN-X buffer: XM
KCl, 20 mM Hepes pH 7.6, 10% glycerol, 0.2% NP-40, 0.1 mM
EDTA, 1 mM DTT, 16 complete inhibitors). Protein-bound
beads were boiled and loaded directly on SDS-PAGE gels.
For the GST-mediated pull-down of recombinant P-TEFb, the
recombinant P-TEFb was produced as described [46]. The GST-
ICP22, GST-193-256 and GST proteins immobilized on beads
were incubated with 300 ng of recombinant P-TEFb in 200 ml of
buffer (250 mM NaCl, 50 mM Tris pH7.5, 1% NP40, 2 mM
EDTA) at 4uC for 1 h. Beads were subsequently washed 36 and
eluted with 10 mM glutathione. Eluted samples were analysed by
western blot.
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